心力衰竭:去年进步和视角。

文章的细节

引用

复制到剪贴板

Tomasoni D, Adamo M,安加罗,冯Haehling年代,外套五角,子宫M

心力衰竭:去年进步和视角。

ESC心脏失败。2020年12月5。doi: 10.1002 / ehf2.13124。

PubMed ID

33277825 (在PubMed

]

文摘

研究必威国际app心力衰竭(HF)在过去几年取得了重大进展。我们给一个更新的最新发现。具有里程碑意义的试验建立了新的治疗心力衰竭与射血分数降低。Sacubitril /缬沙坦在PARADIGM-HF试验优于卡托普利,及其对急性心力衰竭的起始期间住院或出院后初现在可以考虑。最近,开发了新的治疗途径。DAPA-HF和EMPEROR-Reduced试验,dapagliflozin和empagliflozin降低风险的主要复合终点,与安慰剂比较(风险比(人力资源)0.74;95%可信区间(CI) 0.65 - -0.85;P < 0.001和0.75人力资源;95%可信区间0.65 - -0.86;分别为P < 0.001)。 Second, vericiguat, an oral soluble guanylate cyclase stimulator, reduced the composite endpoint of cardiovascular death or HF hospitalization vs. placebo (HR 0.90; 95% CI 0.82-0.98; P = 0.02). On the other hand, both the diagnosis and treatment of HF with preserved ejection fraction, as well as management of advanced HF and acute HF, remain challenging. A better phenotyping of patients with HF would be helpful for prognostic stratification and treatment selection. Further aspects, such as the use of devices, treatment of arrhythmias, and percutaneous treatment of valvular heart disease in patients with HF, are also discussed and reviewed in this article.

DrugBank数据引用了这篇文章

药物

Vericiguat